Trial · NCT00509795
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ranibizumab 0.5mg Q4 | 306 | |
| Overall Study | STARTED | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | 304 | |
| Overall Study | STARTED | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | 304 | |
| Overall Study | STARTED | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | 303 | |
| Overall Study | Patients Received Treatment (SAF) | Ranibizumab 0.5mg Q4 | 304 | |
| Overall Study | Patients Received Treatment (SAF) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | 304 | |
| Overall Study | Patients Received Treatment (SAF) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | 304 | |
| Overall Study | Patients Received Treatment (SAF) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | 303 | |
| Overall Study | Full Analysis Set (FAS) Population | Ranibizumab 0.5mg Q4 | 304 | |
| Overall Study | Full Analysis Set (FAS) Population | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | 304 | |
| Overall Study | Full Analysis Set (FAS) Population | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | 301 | |
| Overall Study | Full Analysis Set (FAS) Population | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | 301 | |
| Overall Study | Per Protocol Set (PPS) Population | Ranibizumab 0.5mg Q4 | 269 | |
| Overall Study | Per Protocol Set (PPS) Population | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | 285 | |
| Overall Study | Per Protocol Set (PPS) Population | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | 270 | |
| Overall Study | Per Protocol Set (PPS) Population | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | 265 | |
| Overall Study | COMPLETED | Ranibizumab 0.5mg Q4 | 284 | |
| Overall Study | COMPLETED | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | 293 | |
| Overall Study | COMPLETED | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | 277 | |
| Overall Study | COMPLETED | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | 276 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00509795/flow